WO2004003559A1 - Assay device for liquid sample - Google Patents
Assay device for liquid sample Download PDFInfo
- Publication number
- WO2004003559A1 WO2004003559A1 PCT/GB2003/002765 GB0302765W WO2004003559A1 WO 2004003559 A1 WO2004003559 A1 WO 2004003559A1 GB 0302765 W GB0302765 W GB 0302765W WO 2004003559 A1 WO2004003559 A1 WO 2004003559A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- assay device
- sample
- liquid
- generation means
- signal generation
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 81
- 238000003556 assay Methods 0.000 title claims abstract description 80
- 239000012491 analyte Substances 0.000 claims abstract description 47
- 239000000020 Nitrocellulose Substances 0.000 claims abstract description 45
- 229920001220 nitrocellulos Polymers 0.000 claims abstract description 45
- 238000012360 testing method Methods 0.000 claims abstract description 44
- 239000000463 material Substances 0.000 claims abstract description 37
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 claims abstract description 36
- 238000001514 detection method Methods 0.000 claims abstract description 26
- 230000008859 change Effects 0.000 claims abstract description 11
- 238000009736 wetting Methods 0.000 claims abstract description 9
- 230000036046 immunoreaction Effects 0.000 claims abstract description 3
- 239000007793 ph indicator Substances 0.000 claims description 6
- 230000002452 interceptive effect Effects 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 description 86
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 43
- 229940079938 nitrocellulose Drugs 0.000 description 43
- 239000010410 layer Substances 0.000 description 23
- 239000000975 dye Substances 0.000 description 13
- 229920002799 BoPET Polymers 0.000 description 12
- 239000005041 Mylar™ Substances 0.000 description 12
- 239000012530 fluid Substances 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 239000004033 plastic Substances 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- -1 Quinalidine Red Chemical compound 0.000 description 4
- 238000009739 binding Methods 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000009597 pregnancy test Methods 0.000 description 3
- 238000007639 printing Methods 0.000 description 3
- 239000011241 protective layer Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000000549 coloured material Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- UWOVWIIOKHRNKU-UHFFFAOYSA-N 2,6-diphenyl-4-(2,4,6-triphenylpyridin-1-ium-1-yl)phenolate Chemical group [O-]C1=C(C=2C=CC=CC=2)C=C([N+]=2C(=CC(=CC=2C=2C=CC=CC=2)C=2C=CC=CC=2)C=2C=CC=CC=2)C=C1C1=CC=CC=C1 UWOVWIIOKHRNKU-UHFFFAOYSA-N 0.000 description 1
- GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 description 1
- 229920001562 poly(N-(2-hydroxypropyl)methacrylamide) Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
Definitions
- the invention relates in general to the field of assay devices for measuring an analyte in a liquid sample and, more particularly, to such assay devices having a sample presence signal generation means.
- a number of assay devices for use in the measurement of one or more analytes in a liquid sample are known. Some of these are complex devices for use by trained personnel; for example, sampling devices for industrial liquids, water etc. or laboratory tests on blood, urine and the like.
- an important category of assay devices includes those intended for home use by consumers, for example home pregnancy test kits.
- Home pregnancy test kits typically function by determining the amount of the hormone human chorionic gonadotrophin (hCG) in a urine sample, and normally provide a visible indication as to whether a subject is pregnant.
- hCG human chorionic gonadotrophin
- EP 291194 discloses a lateral flow assay device whereby sample is introduced onto a porous carrier such as nitrocellulose which has been pretreated with a mobilisable labelled first species such as an antibody capable of binding with the analyte of interest.
- a mobilisable labelled first species such as an antibody capable of binding with the analyte of interest.
- the labelled analyte-antibody complex then permeates into an analyte detection region whereupon it reaches a second species (antibody), immobilised on the porous carrier, which binds the complex.
- the second species is immobilised in a stripe across the carrier such that, in the presence of analyte, a test signal in the form of a line will appear in the analyte detection region due to concentrating of the label, typically gold or dyed latex.
- Such assay devices are used amongst others by users wishing to tell whether they are pregnant, i.e. to detect the presence of the pregnancy hormone hCG. Such users may be using the assay device for the first time or may be a highly emotional state. Furthermore, the test will normally be carried out and interpreted by someone who typically will not be clinically trained. Thus, it is advantageous to have an assay device which is both accurate and reassuring to the user, providing as little ambiguity as possible.
- a control region is typically present.
- an immobilised species is present which is able to bind to the labelled first species.
- the control region serves to indicate that in the absence of a positive result, the assay device was both functioning properly and used correctly. It thus indicates that enough sample had been added and that the labelled species was present and was able to permeate along the porous carrier, i.e. that there are no blockages or manufacturing defects etc.
- the control region is typically downstream of the test region. However, the strength of the signal formed at the control region will depend upon the level of analyte present. A high level of analyte will arguably bind more of the mobilised species leaving less unbound species to reach and bind at the control line.
- EP 355244 (Abbott Laboratories) discloses such a control region (e.g. denoted by reference numeral 32 in Figure lc) which is configured as a n inus sign (see claim 3 and Figures lb and lc) perpendicular to the direction of flow.
- the minus sign is also designed to bisect the read (vertical) line such that, in the absence of analyte, only a minus sign is formed, and in the presence of analyte, a plus sign is formed.
- a capture zone such as a line disposed parallel to the direction of flow
- binding of the labelled species takes place preferentially at the leading front edge.
- a strong signal will be observed at the "beginning" of the line which will fade out along its length. This is undesirable from the point of view of a consumer, as the consumer will want to be reassured by the presence of a bold and unambiguous line.
- EP 421294 discloses an offset symbol (see Figure 6).
- the test signal and control signal are produced at an angle (denoted by reference letter "C” in Figure 6) to the direction of fluid flow overcoming the problem of signal fade out.
- C reference letter
- an offset cross may not be instantly recognisable as a "plus” sign indicative of a positive result, nor would an angled line be necessarily recognisable as a "minus" sign indicative of a negative result.
- control signal may be a line perpendicular to the direction of flow, which resembles the test signal. In the presence of analyte, two vertical lines are seen. However, in the absence of analyte, only the control signal line is seen, i.e. no visible signal is formed in the analyte detection region. The inventors have found that the absence of a line of any sort in the analyte detection region, following performance of the assay, is undesirable to consumers.
- the assay device of the present invention provides a sample presence signal generation means instead of or as well as a control signal generation means.
- Preferred embodiments provide a way to give a visible signal in the plus/minus format or other formats, including but not limited to those formats where the test signal and a further signal interact to form a specific symbol free from signal fadeout without having to resort to character offset.
- the signal is generated solely as a consequence of the carrier being wetted by sufficient liquid sample, namely when taken alone is not indicative of a valid negative result since it provides no indication that the test has functioned properly other than that it has been wetted by sufficient liquid sample.
- the sample presence signal generation means of the present invention functions in a different way to a control signal generation means of the type disclosed in the prior art.
- the resulting sample presence signal does not provide information as to whether a labelled antibody (which has a role in forming a test and/or control signal) has been mobilised and permeated along a carrier, nor whether a labelled antibody is functioning correctly (eg that a particular specific binding property has been conserved).
- the sample presence signal generation means may be positioned anywhere along the carrier although preferably it is positioned downstream from it or more preferably within the analyte detection region.
- a conventional control signal generation means is preferably present in addition, distantly located from a test signal (e.g. in the form of a read line) and sample presence signal (e.g. in the form of a sample indicator line).
- a preferred embodiment of the invention enables a sample presence indicator line to be disposed parallel to the direction of flow of the sample without signal diminishment since the sample presence signal line is not formed by an immunoreation.
- an assay device comprising liquid transport means such as a porous carrier adapted to take up a liquid sample and conduct the liquid to an analyte detection region operable to provide a test signal indicative of the presence and/or amount of an analyte in the liquid sample; characterised in that the assay device further comprises a sample presence signal generation means.
- the sample presence signal generation means generates a sample presence signal in the analyte detection region.
- the sample presence generation means generates a sample presence signal which interacts with the test signal in the presence of analyte to form an interactive symbol representative of a positive result.
- antigen refers to specific binding reactions between an antigen and an antibody.
- Antibodies include proteins designed to bind to antigens and produced by an animal's immune system or synthetic immune system technologies such as phage display or ribosome display, and includes single chain variable fragments, Fab fragments and other peptides derived from antibodies.
- control refers to a signal which indicates that a valid assay result has been achieved. Thus, it must indicate that one or more of the reagents, which have a role in providing the test and/or control signals, are present in functional form.
- An example of such a control is given in EP 0560411, wherein the control zone contains immobilised antibody or analyte that can bind to the labelled reagent.
- interactive symbol when applied to the test signal and sample presence signals, means that the two signals together form a symbol which a user will typically understand as an indicator having a semantic meaning as a whole. For example, if the test signal and sample presence signal together form a cross, this will be perceived as a single symbol having its own semantic meaning: a positive result. Even if the two signals are not directly in contact, they may still interact if they are sufficiently close together to be viewed together. For example, two lines side by side within an analyte detection region or a picture formed from discrete lines can be interactive.
- the present invention provides an assay device which generates a signal indicative of the addition of a liquid to the device, the signal being formed irrespective of the presence of absence of the analyte of interest, and wherein the signal does not provide information as to whether a labelled antibody has been mobilised and permeated along a carrier in correctly functioning form.
- the assay device has a casing, the casing having a first window therein though which the test signal and sample presence signal are viewable, when formed.
- This window may delimit the analyte detection region, encouraging the user to view the contents of the window as forming an interactive symbol with a particular semantic meaning; for example, where a first combination of signals indicate a first outcome of the test and a second combination of signals indicate a second outcome of the test.
- the sample presence signal resembles a minus sign.
- the sample presence signal is oriented parallel to the direction of flow of the liquid sample in the liquid transporting means.
- the sample presence signal interacts with the test signal, to form a symbol (such as a "plus" sign) which represents a positive result when the analyte of interest is present.
- the test signal is in the form of an elongate patch orthogonal to the direction of fluid flow.
- the test signal intersects the sample presence signal and so forms a plus sign when the test result is positive.
- the assay device further comprises a control signal generation means downstream of the analyte detection region adapted to generate a control signal indicative that one or more reagents present in the assay device are functioning.
- the control signal generation means is preferably located in a second window.
- the window may be any means through which the test signal and/or sample presence signal generation means can be viewed, for example an aperture.
- an aperture may be open or may have a transparent protective layer in, above and/or underneath the aperture.
- the signal generated may be any such that a difference in reading may be easily and readily ascertained before and after the sample presence indicator means has been wetted with sufficient sample. Such means however should not interfere with the assay result itself.
- the liquid transporting strip comprises material which, when dry, is substantially opaque but which, when wet, becomes transparent.
- the liquid transport means may advantageously comprise several portions; for example, a wick portion for initially contacting the liquid sample and a porous nitrocellulose strip portion in fluid communication with the wick.
- the analyte detection region and the sample presence signal generation means are located on the liquid transporting strip means.
- the liquid transport means comprises a liquid transporting strip, especially a strip of bibulous material; for example, a porous carrier, such as a nitrocellulose strip.
- the liquid transporting strip comprises material which, when dry, is substantially opaque but which, when wet, becomes transparent.
- the liquid transport means may advantageously comprise several portions; for example, a wick portion for initially contacting the liquid sample and a porous nitrocellulose strip portion in fluid communication with the wick.
- the analyte detection region and the control sample presence generation means are located on the liquid transporting strip means.
- the assay device has a surface visible to the user and the sample presence signal generation means comprises a coloured portion which is not on the surface visible to the user and which is overlaid by a material which, when dry, is substantially opaque and which initially obscures at least a part (preferably all) of the coloured portion (typically located within the aperture) but which, when wet, is sufficiently translucent or transparent to allow at least the initially obscured part of the coloured portion to become visible to the user.
- coloured we mean that the coloured portion is any colour which is discernibly different, to a human observer, to that of the surrounding (and overlying) test strip when wet.
- the embodiment defined in the previous paragraph enables a visible indication to be provided which is of particular convenience, as the shape, size, and colour of the coloured portion may readily be selected for any particular application.
- the coloured portion may be black or one or more colours, a shape or pattern, text, a message, or any other visible indication.
- a clear, unambiguous line or other shape can therefore be provided at any angle or orientation without fadeout.
- the strength or magnitude of the sample presence signal generation means is comparable to that of the test signal when a particular result, for example the presence of analyte, is determined.
- a coloured portion may be selected to have specified optical properties, such as one or more colours, a shape or pattern, text, a message, or any other visible indication, means that this aim can readily be achieved.
- the coloured portion may be part of, or associated with, the liquid transporting strip, for example in the form of a pre-fabricated or imprinted layer, or a sheet applied or a block in contact with the liquid transporting strip or sufficiently close to the liquid transporting strip to be visible therethrough when the strip is rendered transparent by wetting.
- a sheet may be attached by adhesive, although in a preferred embodiment, the sheet is a plastics or other material portion pressed against the liquid transporting strip.
- the sheet may be pressed against the liquid transporting strip means by a protruberance from the assay device casing, which protruberance may be rigid or resiliently deformable.
- the liquid transporting strip comprises a nitrocellulose strip backed with a backing layer, such as mylar.
- the coloured portion comprises a coloured piece of plastics material in contact with the nitrocellulose layer with the mylar layer being uppermost in the device window.
- the piece of plastics material may be part of the casing of the assay device.
- the coloured portion presses upon the liquid transporting strip means. It is perhaps surprising that this works as one would have thought it would interfere with liquid flow in the liquid transporting strip means.
- the coloured portion may be printed on the backing layer.
- the coloured portion may be printed or otherwise formed on a sheet of mylar or other plastics material which is affixed to the side of the nitrocellulose strip not visible to a user; this may be the backing layer side but preferably the sheet is in direct contact with the nitrocellulose.
- a line may be printed or otherwise formed or deposited on the side of the nitrocellulose strip that is not presented to the user using an ink which does not penetrate through the nitrocellulose strip.
- the assay device may be of otherwise conventional construction, similar to that disclosed in EP 291194 or EP 560411.
- the assay device will typically have a porous sample wick intended for the collection of the liquid sample which is in fluid connection with the liquid transporting strip means.
- a porous sample wick intended for the collection of the liquid sample which is in fluid connection with the liquid transporting strip means.
- the sample collected by the porous sample wick flows on the liquid transporting strip means whereby it travels towards the analyte detection region.
- the sample presence signal generation means alternatively comprises a mobilisable detectable material such as an ink spot or a coloured dye, which is localised on or in the liquid transport means and which when wetted by the liquid sample, is carried by it along the liquid transport means resulting in a streaked line generally parallel with the sample flow direction.
- This streaked line provides a "minus" sign and again is independent of any binding reaction and therefore not subject to any signal diminishment. Since the streaked line will continue to be formed along the liquid transport means as the liquid sample progresses, the control signal generation means, if present, may be offset from the flow path of the sample presence signal such that it does not interfere with the control signal.
- the resulting coloured streak provides a visible indication to a user that sufficient liquid sample has been taken up.
- the mobilisable detectable material may comprise a coloured material such as an ink spot or a coloured dye, or a colour-forming material such as a pH indicator which changes colour or an enzyme which catalyses formation of a coloured material.
- a coloured material such as an ink spot or a coloured dye
- a colour-forming material such as a pH indicator which changes colour or an enzyme which catalyses formation of a coloured material.
- a localised patch or spot of coloured or colour-forming material may be located on the liquid transporting strip means, thereby simplifying manufacture.
- the assay device will further comprise a window through which both the sample presence signal, such as a coloured streak, when formed, and the test result, when formed can be seen.
- the patch or spot of coloured or colour-forming material is located outside of the window, so that the coloured or colour-forming material can only be seen once the streak has been formed.
- the patch or spot of coloured or colour-forming material may be obscured prior to use, e.g. by concealment beneath an opaque material such as an adhesive sheet or label or the like.
- the coloured or colour-forming material has appropriate properties and is present in an appropriate amount to give a coloured sample presence indicator or streak which is of similar visible appearance to the test signal when a positive test result is indicated.
- a possible problem with such a device if it also has a control signal generation means, downstream from the patch or spot of coloured or colour-forming material, is that the streak may continue to migrate into the control signal generation means, thereby causing a confusing additional signal to be formed offset from the flow path of the sample presence indicator streak.
- Such a problem is preferably solved by providing the control signal generation means offset from the streak.
- the localised patch or spot is centered on the liquid transporting strip means and the control signal generation region is off-centre.
- the control signal generation region may be in a window offset from the flow path of the sample presence indicator signal or streak.
- the sample presence signal generation means comprises a material immobilised thereon which is adapted to change a visual property in response to wetting.
- the visual property which changes is the colour of the material.
- the material may be adapted to change a visual property in response to wetting by any substance or, more preferably, in response to the presence of a liquid (e.g. a sample of interest) having specific properties.
- a liquid e.g. a sample of interest
- the sample presence signal generation means can be shaped as is desired to give a particular indication.
- a suitable material is a solvatochromic dye, a pH indicator, or a chromoreactand. Such materials will change colour either in response to wetting, or to wetting with specific liquids or liquids with specific properties, such as polarity.
- solvatochromatic dye is Reichardt's dye.
- suitable pH indicators are Bromocresol Green, Phloxine B, Quinalidine Red, Bromophenol Blue etc. In this respect reference is made to corresponding application no. EP 02250121.7, filed 9 th January 2002.
- An indicator could be immobilised with a buffer or other substance e.g. acid or alkali to control its pH and hence its initial colour.
- the indicator would be selected such that it would change colour when contacted with the sample e.g. urine.
- a buffer or other compound e.g. acid or alkali could be added to the device upstream from the indicator that would be solubilised by the sample and ensure that the pH of the sample was such that a dramatic pH change and hence colour change occurred when the sample contacted the indicator.
- Suitable indicators could be immobilised on the membrane by entrapping them within hydrophilic polymers such as Poly 2-Hydroxy ethyl methacrylate (poly(HEMA)) or poly Hydroxy Propyl Methacrylate (poly(HPMA)).
- hydrophilic polymers such as Poly 2-Hydroxy ethyl methacrylate (poly(HEMA)) or poly Hydroxy Propyl Methacrylate (poly(HPMA)).
- poly(HEMA) Poly 2-Hydroxy ethyl methacrylate
- HPMA poly Hydroxy Propyl Methacrylate
- a water insoluble dye could be applied in a solvent that is then evaporated off, leaving behind the water insoluble pH indicator dye.
- some indicator dyes can be fixed by heat or U.N. irradiation.
- a dye could be selected that binds to nitro-cellulose via a hydrophobic interaction (in the same way that proteins bind to nitro-cellulose) or the indicator could be used to dye a carrier molecule (such as a protein or micro-sphere) that would itself bind to the nitro-cellulose.
- Figure 1 is a cross section through an assay device according to the present invention.
- Figure 2 is an enlarged view of part of the assay device shown in Figure 1 ;
- Figure 3 is a plan view of part of the assay device of Figure 1 ;
- Figure 4 is a cross-section through part of an assay device according to an exemplified embodiment of the invention.
- Figure 5 is a cross-section through a part of a further exemplified assay device in accordance with the invention
- Figure 6 is a cross . section through a part of a further exemplified assay device in accordance with the invention
- Figure 7 is a cross section through a part of a still further exemplified assay device in accordance with the invention.
- Figures 8(a)-(d) show photographic images of an assay device in accordance with the invention (a) without top cover or nitrocellulose strip, (b) in assembled form, (c) indicating that a sample is present, and (d) showing a positive result;
- Figures 9(a)-(c) shows an assay device according to further embodiment of the invention, (a) before a measurement is made; (b) after a measurement is made, indicating a positive result; and (c) after contact with a liquid sample, not indicating a positive result;
- Figure 10 is a plan view of the nitrocellulose strip of the assay device shown in Figure 8(a);
- FIGs 11(a) through 11(d) are photographs of sequential development of the sample present signal in the test device shown in Figures 9 and 10;
- Figure 12 is a plan view of a portion of an assay device in accordance with a further embodiment of the present invention.
- Figure 1 is a cross section through an assay device 1 which measures urinary hCG, for use as a pregnancy test device.
- Assay device 1 comprises a case 2, made from a plastics material and having a result window 4 in the form of an aperture.
- a second aperture 5 through which a control signal generation means can be viewed is optional.
- a wick 6 protrudes from the case 2, for drawing up a liquid sample into the device, and a nitrocellulose strip 10 is in fluid communication with the wick 6.
- Case 2 has a protruberance 8 on an inner surface. Protruberance 8 presses against the nitrocellulose strip 10.
- Figure 2 is an illustration of part of Figure 1. This shows that the nitrocellulose strip 10 comprises an initially opaque porous nitrocellulose layer 12, backed by a transparent mylar layer 14.
- Figure 3 is a plan view of the assay device shown in Figure 1 (but to a different scale to Figure 1), showing that a portion of the nitrocellulose strip 10 is visible through result window 4. Initially invisible, there are two regions which can be seen through the result window that may change colour during an assay. Firstly, there is an analyte detection region 16. Nitrocellulose strip 10 has a labelling region 20 ( Figure 1) in which mobile blue latex - labelled mouse anti-hCG antibodies are present. The analyte detection region 16 has immobilised anti-hCG antibodies.
- protruberance 8 (Figure 2) is in the shape of an elongate thin bar, shown as 18, in Figure 3. This is coloured blue, and presses against the nitrocellulose layer 12. It is initially invisible, as the nitrocellulose layer 12 is opaque when it is dry.
- the wick 6 of the assay device 1 is brought into contact with the fluid sample.
- the fluid sample is urine.
- the liquid sample passes up the wick 6, by virtue of the wicking action of the wick.
- the liquid sample then passes along the porous nitrocellulose layer 12, where it carries along mobile labelled antibody from labelling region 20.
- the liquid sample wets the nitrocellulose progressively.
- the labelled anti-hCG antibodies form a sandwich complex with hCG, giving a visible test signal in the analyte detection region 16.
- sample presence signal generation means 18 reveals the protruberance 8, which is now visible and constitutes the sample presence signal.
- the only visible signal apparent to an observer will be the colour of the protruberance 8.
- This sample presence signal on its own resembles a minus sign.
- the analyte detection region 16 will change colour, by virtue of the retained labelled antibodies, giving the test signal. Therefore, the symbol apparent to the user will be a plus symbol, formed by both the test signal and the sample presence signal.
- the user can be confident that sufficient liquid has been added to the assay device and that the assay has given a positive result, which, in this case, indicates that the test subject is pregnant.
- the colour of the protruberance 8 is selected so that it corresponds to the colour of the analyte detection region 16 when it gives a typical positive result. This is not only visually appealing, but gives an additional level of reassurance to the user.
- Figures 8(a)-(d) are a series of photographic images showing (a) a test device, without top cover or nitrocellulose strip 10, in which a coloured plastic protruberance 8 formed in the bottom cover can be seen; (b) an assembled device having a result window 4 and, additionally, an end control window 36 the purpose of which is to provide a sample presence signal line by retaining labelled antibody in a conventional fashion.
- Figure 8(c) shows the device after a test, when no positive result is indicated.
- a minus sign appears in result window 4.
- Figure 8(d) shows device indicating a positive result due to the presence of analyte. Analyte detection region 16 has also changed colour, hence a plus sign is formed.
- Example 2
- FIG. 4 illustrates an example embodiment of the assay device.
- a printed mylar layer 24 is applied to the nitrocellulose strip, in contact with the porous nitrocellulose layer 12. It is held in place by a protruberance 22 supported by the case 2 of the assay device 1.
- a mylar strip 24 enables any type of image to be used merely by printing the image on the mylar strip with conventional printing technology.
- Figure 5 illustrates an alternative embodiment in which a visible image is applied to a mylar layer 26 by means of printing, and the mylar layer is held in contact with the porous nitrocellulose layer 12 by an adhesive layer 28. No protruberance is required in this example, but can optionally be provided.
- Figure 6 illustrates a further example embodiment in which the nitrocellulose strip 10 is inverted, with the mylar backing layer 14 away from the user.
- a coloured image is printed directly onto the mylar layer 14 and simply consists of ink 30 (thickness exaggerated in the Figure).
- an additional protective layer 32 is provided to protect the nitrocellulose strip.
- This protective layer 32 is 50 microns thick Adhesives Research TM laminate, applied by a hand roller. This was found to slow down the movement of liquid through the laminated region which can be of benefit. Again, no protruberance is required but can optionally be provided.
- Example 5 Example 5
- Figure 7 illustrates a further example embodiment in which the nitrocellulose strip is orientated as before, with the mylar layer 14 towards the user.
- An ink layer 34 is printed directly onto the porous nitrocellulose layer 12. It is necessary that this ink does not penetrate through the nitrocellulose layer, and an appropriate ink must be selected for this purpose.
- Figure 9 illustrates in plan view, a schematic of the mtrocellulose strip of an alternative embodiment.
- the casing, wick, analyte detection region and label are as before.
- the nitrocellulose strip 100 is partly visible through a results window 110.
- An ink spot 120 is located on the nitrocellulose strip 100. It is not within the results window 110, and is therefore obscured initially by the assay device case (not shown).
- ink from the ink spot 120 is carried along by the flow of the liquid sample forming a streak 130 which is visible in the results window 110.
- the ink spot is made from an ink selected so that it is neither insufficiently mobile to produce a suitable streak, nor moves entirely with the solvent front so as to not form a streak.
- a reaction zone having immobilised anti-hCG antibodies is also present, forming a coloured bar 140 indicative of a positive result, depending on the presence or amount of analyte in the liquid sample.
- a plus sign is thereby produced, as shown in Figure 9(b).
- Figure 9(c) illustrates the coloured bar 140 on its own, when no positive results is indicated but liquid sample has been added.
- Figure 10 illustrates the nitrocellulose strip 100 for use in this invention.
- the ink spot 120 can be a circular spot, or a rectangular or other shaped mark 120b.
- the ink spot 120 is positioned downstream from a region 125 which, when the device is assembled, is in contact with the wick.
- Holes 145, in the nitrocellulose strip, are provided to engage with formations on the assay device case, holding the nitrocellulose strip in place.
- a suitable ink can be applied using an Ostaline (RTM) rollerball 0.5mm pen.
- RTM Ostaline
- Figure 11 shows the sequential development of the streak using this ink.
- Figure 12 illustrates the nitrocellulose strip of a further example device.
- the mtrocellulose receives a liquid sample from a wick, and is enclosed within a case (not shown) having a results window 202 through which an analyte detection region, which is initially uncovered 204 can be viewed. There is additionally provided a sample presence signal generating region 206.
- the sample presence signal generating region 206 comprises a material which changes colour in the presence of an appropriate liquid sample.
- a pH indicating dye for example, bromocresol green applied in a matrix of cross-linkable poly hydroxy ethyl methacrylate (poly(HEMA)).
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN03820460.6A CN1682114B (en) | 2002-06-27 | 2003-06-26 | Assay device for liquid sample |
EP03761688A EP1521965A1 (en) | 2002-06-27 | 2003-06-26 | Assay device for liquid sample |
CA002491102A CA2491102A1 (en) | 2002-06-27 | 2003-06-26 | Assay device for liquid sample |
DE10392869T DE10392869T5 (en) | 2002-06-27 | 2003-06-26 | Test device for liquid samples |
US10/519,525 US8454903B2 (en) | 2002-06-27 | 2003-06-26 | Assay device for liquid sample |
AU2003253093A AU2003253093B2 (en) | 2002-06-27 | 2003-06-26 | Assay device for liquid sample |
US13/896,782 US8992854B2 (en) | 2002-06-27 | 2013-05-17 | Assay device for liquid sample |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02254517.2 | 2002-06-27 | ||
EP02254517A EP1376131A1 (en) | 2002-06-27 | 2002-06-27 | Assay device for liquid sample |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/519,525 A-371-Of-International US8454903B2 (en) | 2002-06-27 | 2003-06-26 | Assay device for liquid sample |
US13/896,782 Continuation US8992854B2 (en) | 2002-06-27 | 2013-05-17 | Assay device for liquid sample |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004003559A1 true WO2004003559A1 (en) | 2004-01-08 |
Family
ID=29716936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2003/002765 WO2004003559A1 (en) | 2002-06-27 | 2003-06-26 | Assay device for liquid sample |
Country Status (9)
Country | Link |
---|---|
US (2) | US8454903B2 (en) |
EP (2) | EP1376131A1 (en) |
JP (1) | JP3114528U (en) |
CN (1) | CN1682114B (en) |
AU (1) | AU2003253093B2 (en) |
CA (1) | CA2491102A1 (en) |
DE (1) | DE10392869T5 (en) |
ES (1) | ES1061804Y (en) |
WO (1) | WO2004003559A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1861706A1 (en) * | 2005-03-03 | 2007-12-05 | Oakville Hong Kong Co., Limited | Devices and methods for analyte assays with built-in result reporting using recognizable symbols |
WO2007149043A1 (en) * | 2006-06-20 | 2007-12-27 | Åmic AB | Assay device |
US7704753B2 (en) | 2005-03-03 | 2010-04-27 | Inverness Medical Switzerland Gmbh | Devices and methods for analyte assays with built-in result reporting using recognizable symbols |
CN1828301B (en) * | 2005-03-03 | 2010-10-06 | 因韦尔尼斯医药瑞士股份有限公司 | Device for displaying detection result of specimen using visual sign |
DE102010032718A1 (en) * | 2010-07-23 | 2012-01-26 | Christoph Gienapp | Device for determining presence or amount of human chorionic gonadotropin in e.g. blood, has line element on housing at region of window-like opening, and cooperating with window-like opening for displaying positive presence of analytes |
WO2012066235A1 (en) | 2010-11-17 | 2012-05-24 | bioMérieux | Device and method for immunotrials |
WO2012172232A1 (en) | 2011-06-16 | 2012-12-20 | bioMérieux | Device and method for immunoassays |
WO2016097596A1 (en) | 2014-12-16 | 2016-06-23 | bioMérieux | Method and device for determining the presence of a micro-organism in stools with activated carbon pretreatment |
WO2017121963A1 (en) | 2016-01-14 | 2017-07-20 | bioMérieux | Process for determining a humoral response in an immunodepressed patient |
US10328427B2 (en) | 2013-12-04 | 2019-06-25 | Spd Swiss Precision Diagnostics Gmbh | Assay device |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4603547B2 (en) * | 2003-09-11 | 2010-12-22 | セラノス, インコーポレイテッド | Medical devices for analyte monitoring and drug delivery |
US7943395B2 (en) | 2003-11-21 | 2011-05-17 | Kimberly-Clark Worldwide, Inc. | Extension of the dynamic detection range of assay devices |
US7713748B2 (en) | 2003-11-21 | 2010-05-11 | Kimberly-Clark Worldwide, Inc. | Method of reducing the sensitivity of assay devices |
EP1564556A1 (en) * | 2004-02-17 | 2005-08-17 | DST Diagnostic Science & Technology GmbH | Method and apparatus for assaying several analytes simultaneously with an internal control |
EP1669758A1 (en) * | 2004-12-01 | 2006-06-14 | The Jordanian Pharmaceutical Manufacturing Co. | Lateral-flow test device providing improved test result validity |
US7297502B2 (en) * | 2004-12-17 | 2007-11-20 | Oakville Hong Kong Company Limited | Devices and methods for analyte assays with built-in result reporting using recognizable symbols |
US7939342B2 (en) | 2005-03-30 | 2011-05-10 | Kimberly-Clark Worldwide, Inc. | Diagnostic test kits employing an internal calibration system |
JP2008544214A (en) * | 2005-05-09 | 2008-12-04 | セラノス, インコーポレイテッド | Point-of-care fluid system and use thereof |
US7794656B2 (en) | 2006-01-23 | 2010-09-14 | Quidel Corporation | Device for handling and analysis of a biological sample |
US7871568B2 (en) | 2006-01-23 | 2011-01-18 | Quidel Corporation | Rapid test apparatus |
US11287421B2 (en) | 2006-03-24 | 2022-03-29 | Labrador Diagnostics Llc | Systems and methods of sample processing and fluid control in a fluidic system |
US8741230B2 (en) | 2006-03-24 | 2014-06-03 | Theranos, Inc. | Systems and methods of sample processing and fluid control in a fluidic system |
CN102680680B (en) * | 2006-04-12 | 2015-03-18 | 艾博生物医药(杭州)有限公司 | Detecting device containing non-protein capturing substance on control region |
CN101021531B (en) * | 2006-04-12 | 2012-11-28 | 艾博生物医药(杭州)有限公司 | Detecting device containing non-protein trapping matter on control region |
US8007999B2 (en) | 2006-05-10 | 2011-08-30 | Theranos, Inc. | Real-time detection of influenza virus |
EP1882940A1 (en) * | 2006-07-27 | 2008-01-30 | The Jordanian Pharmaceutical Manufacturing Co. | Chitosan as a colour-fixing agent |
US20080113391A1 (en) | 2006-11-14 | 2008-05-15 | Ian Gibbons | Detection and quantification of analytes in bodily fluids |
US8158430B1 (en) | 2007-08-06 | 2012-04-17 | Theranos, Inc. | Systems and methods of fluidic sample processing |
EP2200744B1 (en) * | 2007-09-14 | 2020-05-27 | Biosensia Patents Limited | An analysis system |
CN101995454B (en) * | 2009-08-13 | 2014-07-23 | 艾博生物医药(杭州)有限公司 | Detecting device and using method thereof |
CN104122385B (en) * | 2009-08-13 | 2016-09-07 | 艾博生物医药(杭州)有限公司 | A kind of detection device and using method thereof |
NZ599873A (en) | 2009-10-19 | 2014-09-26 | Theranos Inc | Integrated health data capture and analysis system |
WO2011102563A1 (en) * | 2010-02-17 | 2011-08-25 | 주식회사 에스디 | Immunoassay device and immunoassay method using same |
EP2555871B1 (en) | 2010-04-07 | 2021-01-13 | Biosensia Patents Limited | Flow control device for assays |
US8828329B2 (en) | 2010-10-01 | 2014-09-09 | Church & Dwight, Co., Inc. | Electronic analyte assaying device |
CA2849980A1 (en) * | 2011-09-27 | 2013-04-04 | Diagnostics For All, Inc. | Quantitative microfluidic devices |
GB2509338B (en) * | 2012-11-16 | 2017-09-27 | Essentra Packaging & Security Ltd | Moisture control label |
US10073069B2 (en) | 2013-04-23 | 2018-09-11 | Cordant Research Solutions, Llc | Systems and methods to determine body drug concentration from an oral fluid |
US20150044707A1 (en) * | 2014-02-18 | 2015-02-12 | Melinda Sanders | At-Home Blood Pregnancy Test Kit |
WO2015138343A1 (en) | 2014-03-10 | 2015-09-17 | Click Diagnostics, Inc. | Cartridge-based thermocycler |
US9623415B2 (en) | 2014-12-31 | 2017-04-18 | Click Diagnostics, Inc. | Devices and methods for molecular diagnostic testing |
US10386376B2 (en) | 2015-11-09 | 2019-08-20 | Jeimei, Llc | Sample container with integrated test strip |
US10987674B2 (en) | 2016-04-22 | 2021-04-27 | Visby Medical, Inc. | Printed circuit board heater for an amplification module |
WO2017197040A1 (en) | 2016-05-11 | 2017-11-16 | Click Diagnostics, Inc. | Devices and methods for nucleic acid extraction |
USD800331S1 (en) | 2016-06-29 | 2017-10-17 | Click Diagnostics, Inc. | Molecular diagnostic device |
EP3478857A1 (en) | 2016-06-29 | 2019-05-08 | Click Diagnostics, Inc. | Devices and methods for the detection of molecules using a flow cell |
USD800913S1 (en) | 2016-06-30 | 2017-10-24 | Click Diagnostics, Inc. | Detection window for molecular diagnostic device |
USD800914S1 (en) | 2016-06-30 | 2017-10-24 | Click Diagnostics, Inc. | Status indicator for molecular diagnostic device |
GB2552842B (en) * | 2016-08-12 | 2019-08-28 | Aspirate N Go Ltd | Aspirators |
EP3617694A4 (en) * | 2017-04-28 | 2020-12-30 | Leadway (HK) Limited | Detection device and sample detection method capable of visually reading test results |
CN113295681A (en) * | 2017-04-28 | 2021-08-24 | 利多(香港)有限公司 | Detection device for detecting analyte in sample, detection plate and method for forming easily-identified detection result |
CN108802018B (en) * | 2017-04-28 | 2022-02-22 | 利多(香港)有限公司 | Method capable of visually reading detection result and manufacturing method of detection device |
CN107741420B (en) * | 2017-10-16 | 2021-03-26 | 祁忆青 | Device for rapidly detecting formaldehyde release amount and test paper preparation method |
CA3078976A1 (en) | 2017-11-09 | 2019-05-16 | Visby Medical, Inc. | Portable molecular diagnostic device and methods for the detection of target viruses |
CN107727851A (en) * | 2017-11-15 | 2018-02-23 | 北京舜雷科技有限公司 | The system for detecting HIT antibody that a kind of immune agglutination and colloid gold chromatographic test paper strip are combined |
CN110890015A (en) * | 2018-09-09 | 2020-03-17 | 迈博高分子材料(宁波)有限公司 | Imbibition indicating part and liquid detection device |
EP3988935A1 (en) * | 2020-10-23 | 2022-04-27 | Zhejiang Orient Gene Biotech Co., LTD | Device for analyte assays with built-in result reporting using recognizable symbols |
US12038402B1 (en) * | 2022-05-16 | 2024-07-16 | John Lemke | Moisture detection systems and devices |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4705513A (en) * | 1986-06-27 | 1987-11-10 | Sidney Sheldon | Disposable diaper with wetness indicator |
EP0421294A2 (en) * | 1989-10-05 | 1991-04-10 | Abbott Laboratories | Improved self-performing immunochromatographic device |
US5110550A (en) * | 1988-07-30 | 1992-05-05 | Boehringer Mannheim Gmbh | Test carrier for the analytical determination of a component of a liquid sample |
EP0560411A2 (en) * | 1987-04-27 | 1993-09-15 | Unilever N.V. | A test device for performing specific binding assays |
WO1998022824A1 (en) * | 1996-11-18 | 1998-05-28 | Avraham Zer | Immunochromatography test strips |
WO2003023371A1 (en) * | 2001-09-10 | 2003-03-20 | Quidel Corporation | Method for adding an apparent non-signal line to a rapid diagnostic assay |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5622871A (en) * | 1987-04-27 | 1997-04-22 | Unilever Patent Holdings B.V. | Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents |
US5468648A (en) * | 1991-05-29 | 1995-11-21 | Smithkline Diagnostics, Inc. | Interrupted-flow assay device |
-
2002
- 2002-06-27 EP EP02254517A patent/EP1376131A1/en not_active Withdrawn
-
2003
- 2003-06-26 ES ES200550001U patent/ES1061804Y/en not_active Expired - Fee Related
- 2003-06-26 CA CA002491102A patent/CA2491102A1/en not_active Abandoned
- 2003-06-26 US US10/519,525 patent/US8454903B2/en active Active
- 2003-06-26 WO PCT/GB2003/002765 patent/WO2004003559A1/en active Application Filing
- 2003-06-26 AU AU2003253093A patent/AU2003253093B2/en not_active Expired
- 2003-06-26 DE DE10392869T patent/DE10392869T5/en not_active Withdrawn
- 2003-06-26 CN CN03820460.6A patent/CN1682114B/en not_active Expired - Lifetime
- 2003-06-26 EP EP03761688A patent/EP1521965A1/en not_active Withdrawn
-
2005
- 2005-05-19 JP JP2005003418U patent/JP3114528U/en not_active Expired - Lifetime
-
2013
- 2013-05-17 US US13/896,782 patent/US8992854B2/en not_active Expired - Lifetime
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4705513A (en) * | 1986-06-27 | 1987-11-10 | Sidney Sheldon | Disposable diaper with wetness indicator |
EP0560411A2 (en) * | 1987-04-27 | 1993-09-15 | Unilever N.V. | A test device for performing specific binding assays |
US5110550A (en) * | 1988-07-30 | 1992-05-05 | Boehringer Mannheim Gmbh | Test carrier for the analytical determination of a component of a liquid sample |
EP0421294A2 (en) * | 1989-10-05 | 1991-04-10 | Abbott Laboratories | Improved self-performing immunochromatographic device |
WO1998022824A1 (en) * | 1996-11-18 | 1998-05-28 | Avraham Zer | Immunochromatography test strips |
WO2003023371A1 (en) * | 2001-09-10 | 2003-03-20 | Quidel Corporation | Method for adding an apparent non-signal line to a rapid diagnostic assay |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1828301B (en) * | 2005-03-03 | 2010-10-06 | 因韦尔尼斯医药瑞士股份有限公司 | Device for displaying detection result of specimen using visual sign |
EP1861706A1 (en) * | 2005-03-03 | 2007-12-05 | Oakville Hong Kong Co., Limited | Devices and methods for analyte assays with built-in result reporting using recognizable symbols |
EP1861706A4 (en) * | 2005-03-03 | 2008-10-22 | Oakville Hong Kong Co Ltd | Devices and methods for analyte assays with built-in result reporting using recognizable symbols |
US7704753B2 (en) | 2005-03-03 | 2010-04-27 | Inverness Medical Switzerland Gmbh | Devices and methods for analyte assays with built-in result reporting using recognizable symbols |
US8759115B2 (en) | 2006-06-20 | 2014-06-24 | Johnson & Johnson Ab | Assay device |
US8343439B2 (en) | 2006-06-20 | 2013-01-01 | Amic Ab | Assay device |
WO2007149043A1 (en) * | 2006-06-20 | 2007-12-27 | Åmic AB | Assay device |
DE102010032718A1 (en) * | 2010-07-23 | 2012-01-26 | Christoph Gienapp | Device for determining presence or amount of human chorionic gonadotropin in e.g. blood, has line element on housing at region of window-like opening, and cooperating with window-like opening for displaying positive presence of analytes |
WO2012066235A1 (en) | 2010-11-17 | 2012-05-24 | bioMérieux | Device and method for immunotrials |
WO2012172232A1 (en) | 2011-06-16 | 2012-12-20 | bioMérieux | Device and method for immunoassays |
US10328427B2 (en) | 2013-12-04 | 2019-06-25 | Spd Swiss Precision Diagnostics Gmbh | Assay device |
WO2016097596A1 (en) | 2014-12-16 | 2016-06-23 | bioMérieux | Method and device for determining the presence of a micro-organism in stools with activated carbon pretreatment |
WO2017121963A1 (en) | 2016-01-14 | 2017-07-20 | bioMérieux | Process for determining a humoral response in an immunodepressed patient |
Also Published As
Publication number | Publication date |
---|---|
ES1061804Y (en) | 2006-07-16 |
US20060029924A1 (en) | 2006-02-09 |
US8992854B2 (en) | 2015-03-31 |
EP1521965A1 (en) | 2005-04-13 |
JP3114528U (en) | 2005-10-27 |
DE10392869T5 (en) | 2005-08-25 |
ES1061804U (en) | 2006-04-01 |
EP1376131A1 (en) | 2004-01-02 |
CA2491102A1 (en) | 2004-01-08 |
CN1682114B (en) | 2010-05-26 |
CN1682114A (en) | 2005-10-12 |
US8454903B2 (en) | 2013-06-04 |
AU2003253093B2 (en) | 2009-02-05 |
US20140093427A1 (en) | 2014-04-03 |
AU2003253093A1 (en) | 2004-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8992854B2 (en) | Assay device for liquid sample | |
US6607922B2 (en) | Immunochromatographic assay method and apparatus | |
EP1410032B1 (en) | Color contrast system for lateral flow immunoassay tests | |
US8389209B2 (en) | Test device for rapid diagnostics | |
US7179657B2 (en) | Method for adding an apparent non-signal line to a rapid diagnostic assay | |
US20080020482A1 (en) | Assay Devices | |
CN104820094A (en) | Immune-chromatographic detection test paper and detection method | |
US7413880B2 (en) | Test kit for immunochromatography | |
EP2622345A1 (en) | Improved electronic analyte assaying device | |
US20080254441A1 (en) | Lateral-Flow Test Device Providing Improved Test Result Validity | |
WO2006080438A1 (en) | Immunochromatographic test instrument and semiquantitative method using the same | |
US9165357B2 (en) | Methods for determining a wavefront position on a test strip | |
JP4425075B2 (en) | Immunochromatography device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004516949 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2491102 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 200450084 Country of ref document: ES Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003253093 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003761688 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038204606 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003761688 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006029924 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10519525 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10519525 Country of ref document: US |